Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China.
Int J Lab Hematol. 2023 Jun;45(3):317-327. doi: 10.1111/ijlh.14024. Epub 2023 Feb 13.
Multiple myeloma (MM) is a fatal hematological malignancy and does not have adequate prognostic indicators. Previous studies indicate that CEP72 is closely related to tumorigenesis and tumor progression. However, the expression and function of CEP72 in multiple myeloma have yet to be elucidated.
In this study, we explored the correlation between CEP72 expression and clinicopathological characteristics as well as the impacts of CEP72 expression on the survival of MM patients. In addition, PPI, GSEA and Chemotherapy drug resistance analysis identified the possible mechanism.
CEP72 is overexpressed in both MM patients and MM cell lines. Clinically, patients in the CEP72 subgroup were significantly older than those in the CEP72 subgroup (p = 0.003). Up-regulation of CEP72 was related to poor overall survival and event-free survival. PPI network showed that CEP72 was related to PCM1, KIZ, OFD1, etc. GSEA analysis showed that CEP72 was enriched in cell cycle, oocyte meiosis, protein export, lysosome and N-glycan biosynthesis pathways. Drug resistance analysis indicated that there was a positive correlation between the CEP72 expression and the IC50 values of 6-mercaptopurine, 8-chloro-adenosine, clofarabine, fludarabine and allopurinol.
High CEP72 expression was a poor prognostic factor in patients diagnosed with multiple myeloma.
多发性骨髓瘤(MM)是一种致命的血液系统恶性肿瘤,目前尚无充分的预后指标。先前的研究表明CEP72 与肿瘤发生和肿瘤进展密切相关。然而,CEP72 在多发性骨髓瘤中的表达和功能尚未阐明。
在本研究中,我们探讨了 CEP72 表达与临床病理特征的相关性,以及 CEP72 表达对 MM 患者生存的影响。此外,通过 PPI、GSEA 和化疗药物耐药性分析,确定了可能的机制。
CEP72 在 MM 患者和 MM 细胞系中均过度表达。临床方面,CEP72 亚组患者明显比 CEP72 亚组患者年龄更大(p=0.003)。CEP72 的上调与总体生存和无事件生存不良相关。PPI 网络显示 CEP72 与 PCM1、KIZ、OFD1 等相关。GSEA 分析表明,CEP72 富集于细胞周期、卵母细胞减数分裂、蛋白输出、溶酶体和 N-糖生物合成途径。耐药性分析表明,CEP72 表达与 6-巯基嘌呤、8-氯腺苷、克拉屈滨、氟达拉滨和别嘌醇的 IC50 值呈正相关。
高 CEP72 表达是多发性骨髓瘤患者预后不良的一个因素。